LYEL - Lyell Immunopharma, Inc.

Lyell Immunopharma, Inc. , a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer.

As of Nov 13, 2026: spot at $14.46, max pain $16.00, GEX (assumed dealer book) -$5.3K of delta per 1% move.

Exposures are the assumed dealer book over the expirations within 30 days of the session, or the first four when none are (1 expiration, through Nov 20, 2026), as of Nov 13, 2026. Assumes dealers are long the calls and short the puts, a share p of open interest each - here 100% of open interest (the GEX page sets the share). A date without a stored exposure is a gap; a value marked * is partial, averaged over fewer days, or may include contracts expiring that day or of an unreadable expiration: its reason is printed beside it.

Sector
Healthcare
Industry
Biotechnology
Market Cap
$351.6M
Beta
-0.07
52-Week Range
7.195-45
CEO
Lynn Seely
Employees
161
IPO Date
Jun 17, 2021
Exchange
NASDAQ

What LYEL Looks Like to Options Traders Today

the assumed dealer book's GEX is negative (-$5.3K of delta per 1% move): its hedging goes with the trend, amplifying realized volatility and accelerating directional moves where real dealers are positioned like the book; the 25-delta skew (0.146) prices calls richer than puts, often reflecting upside speculation or squeeze risk.

What This Page Covers

The LYEL overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.

Frequently asked LYEL overview questions

What is LYEL?
LYEL is the ticker symbol for Lyell Immunopharma, Inc., a listed security. Lyell Immunopharma, Inc. , a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. Listed on NASDAQ. LYEL is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
What does the LYEL options snapshot look like today?
As of Nov 13, 2026, the LYEL options snapshot shows spot at $14.46, max pain $16.00, GEX (assumed dealer book) -$5.3K of delta per 1% move. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, the assumed dealer book's gamma exposure and the put-minus-call delta balance, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
What are LYEL's key statistics?
Lyell Immunopharma, Inc. (LYEL) carries a market capitalization of $351.6M, beta of -0.07 relative to the broader market, 52-week range of 7.195-45. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
What sector or industry does LYEL belong to?
Lyell Immunopharma, Inc. operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare LYEL's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
How current is the LYEL data on this page?
The options snapshot above is dated Nov 13, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, twice-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).